本文關(guān)鍵詞： 共刺激分子 B7-2 PD-L1 CD4~+CD25~+調(diào)節(jié)性T細(xì)胞 乙型肝炎病毒 免疫耐受　出處：《暨南大學(xué)》2009年碩士論文　論文類型：學(xué)位論文

【摘要】： 目的 探討外周血單個核細(xì)胞共刺激分子B7-2和PD-L1及CD4~+CD25~+調(diào)節(jié)性T細(xì)胞FOXP3mRNA表達(dá)在慢性乙型肝炎患者免疫耐受中的作用。 方法 以慢性HBV感染免疫清除期患者30例、免疫耐受期患者10例和健康對照10例為研究對象,用RT-PCR方法研究外周血單個核細(xì)胞共刺激分子B7-2和PD-L1及FOXP3mRNA的表達(dá)水平。 結(jié)果 免疫清除期、免疫耐受期患者和健康對照組B7-2的表達(dá)水平分別為0.826±0.055、0.880±0.036和0.942±0.029;免疫清除期和免疫耐受期患者B7-2的表達(dá)水平均顯著低于健康對照組(P分別為0.000和0.002);免疫清除期患者B7-2的表達(dá)水平低于免疫耐受期患者(P=0.004)。免疫清除期、免疫耐受期患者PD-L1的表達(dá)分別為0.763±0.090、0.741±0.032,均高于健康對照組的0.663±0.040(P分別為0.000和0.000);免疫清除期患者PD-L1的表達(dá)水平高于免疫耐受期患者,但兩者差異沒有統(tǒng)計(jì)學(xué)意義(P=0.564)。免疫清除期、免疫耐受期PD-L1/B7-2比值分別為0.926±0.102、0.842±0.049,均顯著高于健康對照組的0.704±0.042(P分別為0.000和0.000);免疫清除期患者PD-L1/B7-2比值高于免疫耐受期患者,統(tǒng)計(jì)學(xué)處理有顯著性差異(P=0.005)。免疫清除期、免疫耐受期和健康對照FOXP3的表達(dá)分別為0.864±0.085、0.621±0.041和0.603±0.037;免疫清除期患者FOXP3的表達(dá)顯著高于免疫耐受期患者(P=0.000)和健康對照組(P=0.000),免疫耐受期患者FOXP3的表達(dá)稍高于健康對照組,但差異尚無統(tǒng)計(jì)學(xué)意義(P=0.675)。免疫清除期PD-L1/B7-2比值與FOXP3表達(dá)呈顯著正相關(guān)(r=0.491,P=0.006)。 結(jié)論 在慢性HBV感染中,正、負(fù)共刺激分子的變化可能是機(jī)體對免疫反應(yīng)保護(hù)性調(diào)節(jié)的結(jié)果,最終可能使機(jī)體對HBV的免疫耐受加深。正負(fù)共刺激分子和FOXP3 mRNA的表達(dá)有相關(guān)性;共刺激分子和CD4~+CD25~+調(diào)節(jié)性T細(xì)胞可能共同參與調(diào)節(jié)機(jī)體對HBV感染的免疫耐受。
[Abstract]:Purpose Study on the costimulatory molecules B7-2, PD-L1 and CD4 ~ CD25 ~ in peripheral blood mononuclear cells. The role of regulatory T cell FOXP3mRNA expression in immune tolerance in patients with chronic hepatitis B. Method Thirty patients with chronic HBV infection, 10 patients with immune tolerance and 10 healthy controls were studied. The expression levels of B7-2, PD-L1 and FOXP3mRNA in peripheral blood mononuclear cells (PBMC) were studied by RT-PCR. Results The expression levels of B7-2 in the immune clearance phase, the immune tolerance stage patients and the healthy control group were 0.826 鹵0.0555 鹵0.880 鹵0.036 and 0.942 鹵0.029, respectively. The expression of B7-2 in immune clearance phase and immune tolerance stage was significantly lower than that in healthy control group (P = 0.000 and 0.002), respectively. The expression level of B7-2 in patients with immune clearance was lower than that in patients with immune tolerance. The expression of PD-L1 in patients with immune tolerance was 0.763 鹵0.090, 0.741 鹵0.032, respectively. It was 0.000 and 0.000m respectively higher than that of the healthy control group (0.663 鹵0.040). The expression of PD-L1 was higher in patients with immune clearance than in patients with immune tolerance, but there was no significant difference between the two groups. The ratio of PD-L1/B7-2 in immune tolerance phase was 0.926 鹵0.102 鹵0.842 鹵0.049, respectively. All of them were significantly higher than those of the healthy control group (0.704 鹵0.042) P = 0.000 and 0.000, respectively. The ratio of PD-L1/B7-2 in patients with immune clearance was higher than that in patients with immune tolerance. The expression of FOXP3 was 0.864 鹵0.085, 0.621 鹵0.041 and 0.603 鹵0.037 in immune tolerance period and healthy control, respectively. The expression of FOXP3 in patients with immune clearance was significantly higher than that in patients with immune tolerance (0.000) and healthy controls (0.000). The expression of FOXP3 in patients with immune tolerance was slightly higher than that in healthy controls. However, there was no statistical significance between the PD-L1/B7-2 ratio and the expression of FOXP3. There was a significant positive correlation between the PD-L1/B7-2 ratio and the expression of FOXP3. Conclusion In chronic HBV infection, the changes of positive and negative costimulatory molecules may be the result of protective regulation of immune response. The positive and negative costimulatory molecules were correlated with the expression of FOXP3 mRNA. Costimulatory molecules and CD4 ~ CD25 ~ regulatory T cells may be involved in the regulation of immune tolerance to HBV infection.
【學(xué)位授予單位】：暨南大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2009
【分類號】：R392

【共引文獻(xiàn)】

相關(guān)期刊論文 前1條

1 黃鋼;姜曼;白云;;LPS調(diào)節(jié)U937細(xì)胞上B7-H1表達(dá)的初步研究[J];免疫學(xué)雜志;2006年05期

相關(guān)博士學(xué)位論文 前3條

1 彭勇;核因子-κB圈套協(xié)同CTLA4-Ig抗大鼠肝移植急性排斥反應(yīng)的研究[D];重慶醫(yī)科大學(xué);2005年

2 黃鋼;LPS刺激調(diào)控U937細(xì)胞表達(dá)B7-H1機(jī)制的實(shí)驗(yàn)研究[D];第三軍醫(yī)大學(xué);2005年

3 黃保軍;重組腺病毒介導(dǎo)的4-1BBIg基因治療延長小鼠同種心臟移植物存活的實(shí)驗(yàn)研究[D];華中科技大學(xué);2006年

相關(guān)碩士學(xué)位論文 前1條

1 遲曉云;PD-L1和PD-L2在正常人和胃癌患者PBMC及胃組織中的表達(dá)分析[D];暨南大學(xué);2006年

，

本文編號：1465613